ALNY Earnings Date & Options Strategy
Alnylam Pharmaceuticals, Inc.
$165.04
October 29, 2026
Earnings TODAY!
Last Updated: September 05, 2026
Pre-Earnings Catalyst Score, Supply-Chain Domino & Conference Radar
Event-Driven Intelligence
Pre-Earnings Catalyst Scanner
Monitoring
No extreme pre-earnings dip + unusual sweep anomaly flagged today. Monitor IV expansion as the report date approaches.
Analyst EPS Revision Momentum
Net Downward Revisions
+13
Up (7D)
+14
Up (30D)
-20
Down (30D)
Curr Qtr Consensus: $2.42
90D Ago: $2.78
Supply-Chain Domino & Peer Earnings Read-Through
3 Linked Tickers
PFE — Pfizer Inc.
HIGH
Pfizer operates in the same pharmaceutical space and may experience shifts in investor sentiment based on ALNY's performance.
Merck is a direct competitor in the pharmaceutical industry and will be affected by ALNY's earnings results.
JNJ — Johnson & Johnson
MEDIUM
As a major player in the pharmaceutical sector, JNJ could see impacts from ALNY's earnings performance.
Industry Conference & Pre-Drift Radar
1 Event
Jefferies Global Healthcare Conference
(Jefferies)
Presentation Date: Nov 18, 2026
Active Pre-Conference Drift Window
Options IV Analysis
Loading IV data...
Earnings Estimates
EPS Estimate (Current Qtr)
$2.25
EPS Estimate (FY)
$22.68
Earnings Growth (YoY)
+633.5%
Revenue Growth (YoY)
+16.7%
Forward P/E
15.2x
How to Trade Earnings with Options
Buy Options Strategy
Buy options when IV percentile is below 30. This means options are cheap relative to their historical pricing. As earnings approach, IV typically rises (IV expansion), increasing the value of your options even before earnings.
Sell Premium Strategy
Sell options when IV percentile is above 70. After earnings, IV crashes (IV crush), which benefits option sellers. Iron condors and credit spreads profit from this IV collapse.
Timing Tips
- 2-3 weeks before: Best time to buy options if IV is low
- 1 week before: IV starts rising, still okay to buy if IV < 50th percentile
- Day of earnings: IV at peak - avoid buying, consider selling
- After earnings: IV crushes 30-50%, sellers profit
Gamma Positioning
Loading gamma data...
Analyst Ratings
STRONG BUY
33 analysts
Price Target
$492.71
Strong Buy
Buy
Hold
Sell
More ALNY Analysis
Company Info
Company
Alnylam Pharmaceuticals, Inc.
Sector
Healthcare
Industry
Biotechnology